APVO452
Prostate Cancer
PreclinicalActive
Key Facts
About Aptevo Therapeutics
Aptevo Therapeutics is a public, clinical-stage biotech company developing a broad pipeline of bispecific and trispecific immunotherapies for oncology. Its lead candidate, mipletamig, is a CD3/CD123 engager for Acute Myeloid Leukemia (AML), and it has multiple other preclinical and early-stage programs targeting solid tumors. The company faces significant challenges, including a very low market valuation and the high-risk nature of clinical development, but its multi-specific antibody platform represents a potential differentiator in the competitive immuno-oncology space.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Erleada (apalutamide) | Johnson & Johnson | Approved |
| Nubeqa (darolutamide) | Bayer | Approved |
| BIO 300 | Humanetics Corp. | Not Specified |
| Xtandi (enzalutamide) | Astellas Pharma | Approved |
| Proxalutamide (HS-10370) | Hansoh Pharma | Phase 3 |
| Darolutamide (Nubeqa) | Orion Corporation | Approved |
| Relacorilant + Enzalutamide | Corcept Therapeutics | Phase 2 |
| NBTXR3 | Nanobiotix | Phase 1/2 |
| Praluzatamab ravtansine (CX-2009) | CytomX Therapeutics | Phase 1/2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |
| ARV-766 | Arvinas | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Phase 1/2 |